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Nonfused (i.e., nonhybrid) filamentous hemagglutinin (FHA) of BordeteUla pertussis was efficiently expressed
in Escherichia coli K-12 and Salmonella typhimurium aroA at levels higher than those found in wild-type B.
pertussis when the upstream signals of the gene were replaced and the translation initiation region was
engineered to optimize translational efficiency. Inclusion of part of the C-terminal FHA open reading frame,
whose translation product does not appear to be part of the major secreted species of FHA, was shown to be
important in achieving protein expression in both E. coli and S. typhimurium aroA; removal of the downstream
gene sequence abolished recombinant FHA production. The levels of expression observed varied widely
according to the construct and host bacterium used.
Bordetella pertussis is the etiological agent of whooping
cough, a major childhood respiratory disease that can de-
velop serious complications and cause death (46). Although
whole-cell vaccine preparations routinely administered in
combination with diphtheria and tetanus toxoids provide
good protection against severe disease, increasing concern
regarding the side effects of the vaccines has led to de-
creased vaccine acceptability, a decrease in the number of
vaccinated infants, and a consequent increase in the inci-
dence of whooping cough (24).
B. pertussis produces a number of virulence factors,
including pertussis toxin, adenylate cyclase, filamentous
hemagglutinin (FHA), fimbriae, and major outer membrane
proteins, whose synthesis is positively regulated by the
products of the bvg locus (14, 36, 48). Some of these
determinants are potential antigens for inclusion in new-
generation acellular, atoxic, nonreactogenic vaccines (23,
24). One of the most promising components for inclusion in
such a vaccine is FHA, which plays a major role in bacterial
attachment and subsequent colonization of the epithelial
respiratory tract during the early stages of disease (44, 45).
FHA may also facilitate the superinfections that commonly
complicate this disease because other bacteria may utilize
this bridge-acting adhesin (43) and because of the impair-
ment of macrophage responses due to specific interactions
mediated by FHA (20). An immune response against FHA
might prevent infection and disease by inhibiting coloniza-
tion (33), inducing opsonization (10), or stimulating cellular
responses against the invading bacterium.
Problems in the production of FHA for acellular vaccines
include the fermentation of B. pertussis, a human pathogen
(problems in production safety) and a fastidious microorgan-
ism with slow growth rates (long fermentation times, poor
yields), and the contamination of FHA preparations with
other virulence factors (which may contribute to some of the
side effects of vaccination). Here we report the efficient
direct expression of nonfused (i.e., nonhybrid) FHA in
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Escherichia coli. Furthermore, we have obtained expression
of nonfused FHA in a Salmonella typhimurium aroA strain.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial
strains used in this work were as follows. The B. pertussis
strain used was Tohama serotype 1.2 (34). E. coli SURE
(Stratagene) recB recJ sbcC201 uvrC umuC: :TnS (Kn) mcrA
mcrB mrr lac AhsdRMS endAl gyrA96 thi relAl supE44 F'
(proAB lacIqZAM15 TnlO) and E. coli JM109 endAl recAl
hsdR17 supE44 thi gyrA96 A(lac-proAB) F' (traD36 proAB+
lacIqZAM15) (49) were used for transformations when
recombinant clones were screened for ,3-galactosidase alpha
complementation, whereas E. coli CC118 araD139 A(ara
leu)7697 AlacX74 phoA20 galE galK thi-I rpsE (Spr) rpoB
argE(Am) recAl Rif' (17) was used as a recipient strain for
other transformations. E. coli 537(pCI857TS) (22) was used
for the induction of MS2 polymerase fusions. E. coli 876 pep
(R. Brownlie), E. coli EC538 (J. E. G. McCarthy), and E.
coli CAG629 Ion htpR165::TnJO (C. Gross) were used as
recipient strains in induction experiments for the expression
of FHA. E. coli SK5003 F- leu thr Cmr rnb-500 pnp-7 (7)
was used in experiments to assess mRNA degradation. E.
coli K38X(pGP1-2) Kmr (28, 42), BL21 DE3, and BL21
DE3(pLysS) (41) were used for the expression of pT7-7
constructions; S. typhimurium SL5283 (B. A. Stocker), a
galE503 derivative of LB5000 hsdSB121 leu-3121 (31), was
used as an intermediate strain in the transfer of plasmids by
transformation from E. coli to S. typhimurium SL3261 aroA
(12). The plasmids used in this work were pUC18NotI (11),
pEX31A and pEX31B (40), pJLA503 (37), pT7-7 (S. Tabor),
and pRMB2 (2). Plasmid pLG612-1 (I. B. Holland) was used
as a source of the 23-kDa COOH-terminal signal sequence of
hemolysin A, and plasmid pLG575 (16) was used as a source
of the hemolysin B accessory genes.
E. coli and S. typhimurium strains were grown in Luria
broth or on Luria agar (29). 5-Bromo-4-chloro-3-indolyl-,-
D-galactopyranoside medium (29) was used for selection
with the 3-galactosidase alpha complementation system. B.
pertussis was grown on Bordet-Gengou agar base (Difco)
supplemented with 1% glycerol and 15% (vol/vol) defibri-
nated horse blood or in SS-X broth (39). The following
antibiotics were used for selection: ampicillin (100 ,ug/ml),
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3788 GUZMAN ET AL.
chloramphenicol (50 ,ug/ml), and tetracycline (50 p.g/ml).
Broth cultures were aerated by shaking at 200 rpm in a New
Brunswick environmental incubator shaker.
DNA manipulations. Plasmids were isolated by alkaline
lysis (29). Restriction endonuclease digestion, ligation with
T4 DNA ligase, T4 polynucleotide kinase end labeling,
dephosphorylation with fetal calf intestinal phosphatase, and
transformation were performed as described by Sambrook et
al. (29). Enzymes were obtained from Boehringer Mann-
heim. DNA sequencing was carried out by the chain termi-
nation method of Sanger et al. (32). Oligonucleotides were
synthesized with an Applied Biosystems model 380B DNA
synthesizer in accordance with the manufacturer's instruc-
tions.
RNA isolation and primer extension analysis. RNA was
isolated as previously described (47). The FHAa primer (see
below) was labeled at its 5' end with T4 polynucleotide
kinase and [_y-32P]ATP (Amersham). Primer extension was
carried out as described by de Lorenzo et al. (5). Samples
were heated at 80°C for 10 min and electrophoresed as for
DNA sequence analysis.
RNA dot blot hybridization. Total RNA (50 ,ug) was
spotted onto nylon membranes (Pall Biodyne type B;
0.45-,um pore size), fixed by being baked at 80°C for 1 h,
prehybridized, and hybridized with 5'-end-labeled probes as
described by Sambrook et al. (29). Probes complementary to
the coding strand were as follows: (i) FHAa (3'-AGGCAA
TCATTGCGTGCGGGT-5') complementary to nucleotides
194 to 214 of the published jhaB sequence (6, 21); (ii) FHAb
(3'-ACAGCTCGTTCGTCCCGTTCG-5') complementary to
nucleotides 730 to 750; (iii) FHAc (3'-AGGTCGAACCG
CGCCGCTCGT-5') complementary to nucleotides 1228 to
1248; (iv) FHAd (3'-GCTTGTCGCTGCGCCTTAACGC-5')
complementary to nucleotides 1695 to 1717; (v) FHAe (3'-
GCTTGAGCGACGTGCGGTTAG-5') complementary to
nucleotides 2599 to 2619; (vi) FHAf(3'-GTGCTAAAGTGC
CACGTCC-5') complementary to nucleotides 4745 to 4764;
(vii) FHAg (3'-TTCTGCGGAGAAGGCCACTC-5') comple-
mentary to nucleotides 5748 to 5768; (viii) FHAh (3'-AGT
TCCAGCGCTGGAGCTAC-5') complementary to nucleo-
tides 7747 to 7767; (ix) jlaSOJ (3'-AATAGAGACCGCCAC
AACTG-5') complementary to nucleotides 1306 to 1325
upstream of the start of transcription from the PR and PL
promoters in vector pJLA503 (used as a negative control)
(37); and (x) Hlyl (3'-ATAGAAAGTCCTATACCGGT-5')
complementary to nucleotides 3873 to 3892 of the E. coli
hemolysin A gene sequence (8). See Fig. 3C for a graphic
representation of the probes.
Induction experiments. Overnight cultures were diluted to
an A59 of 0.4 with Luria broth, grown at 30°C with shaking
at 200 rpm to an A590 of 0.9, and temperature induced at 42°C
or isopropylthio-,3-D-galactoside (IPTG) induced by the ad-
dition of IPTG to a 1.0 mM final concentration. After
induction, 1 ml of the culture was pelleted and resuspended
in 0.7% NaCl. For protein secretion screening, 0.9 ml of
supernatant fluid was mixed with 100 RI of 100% (wt/vol)
trichloroacetic acid, incubated on ice for 2 h, centrifuged at
3,000 x g for 15 min, washed with 100% ethanol, and
resuspended in 0.7% NaCl. Protein concentrations of sam-
ples were determined by the Lowry procedure as modified
by Sanderman and Strominger (30). Samples were mixed in
a 1:1 ratio with loading buffer (29), and approximately 50 ,ug
of protein was electrophoresed by the procedure of Laemmli
(15) with a 3.85% acrylamide stacking gel and a 10% acryl-
amide separating gel. High-molecular-weight markers were
purchased from Bio-Rad.
FHA purification. FHA was purified from B. pertussis
Tohama by the procedure of Sato et al. (35).
Immunological techniques. Monoclonal antibody P12H3
was kindly provided by C. Parker (9). Polyclonal rabbit
antiserum against FHA was prepared by emulsifying FHA in
Freund's incomplete adjuvant (ratio, 1:1) in a final volume of
1.0 ml and injecting the emulsion subcutaneously and intra-
muscularly into 3-month-old chinchilla bastard rabbits
(Charles River Wiga GmbH) according to the following
regime: day 1, 600 ,ug; day 30, 300 ,ug; and day 40, 300 ,ug.
On day 50, the rabbits were sacrificed and the serum was
collected, pooled, and stored at -20°C until used. Western
blotting (immunoblotting) was carried out essentially as
described by Burnette (3). Prestained molecular weight
markers were purchased from Bio-Rad.
Immunoelectron microscopy. Cells were fixed with 0.5%
formaldehyde and 0.2% glutaraldehyde (final concentra-
tions) in Luria broth for 1 h on ice. After several washings
with 10 mM glycine-50 mM potassium phosphate buffer-
0.9% NaCl (pH 6.9), cells were embedded by the method of
progressive lowering of temperature (27) with Lowicryl
K4M resin, modified as follows: (i) the infiltration with 1 part
ethanol and 1 part K4M resin was done overnight, (ii) the
infiltration with 1 part ethanol and 2 parts K4M resin was
done for 12 h, and (iii) the infiltration with pure resin was
done for 2 days with several changes of the resin. Recombi-
nant FHA was detected with polyclonal antibodies against
FHA that had been cross-absorbed with E. coli and S.
typhimurium aroA and purified by affinity chromatography
with protein A-Sepharose CL-4B. Antibodies bound to
sample preparations were visualized by incubation with
protein A-gold (gold particle size, 10 nm) complexes after
preparation of ultrathin sections (postembedding protocol)
as previously described (25, 26). The protein A-gold com-
plexes were produced by established procedures (38).
Pulse-chase experiments. Cultures were grown to the ex-
ponential phase at 30°C (A590 0.7). A 0.7-ml sample was
removed, and the cells were harvested by centrifugation,
resuspended, and washed with 1.0 ml of minimal M9 medium
(29). After resuspension in 1.0 ml of M9 medium supple-
mented with 0.02% each amino acid except for methionine
and cysteine, the cells were grown for a further 1 h at 30°C.
Cultures were induced at 42°C for 10 min, pulsed with 10 ,uCi
of "5S-methionine (Amersham) for 5 min at 30°C, chased by
centrifugation, and resuspended in supplemented M9 me-
dium containing 0.1% cold methionine. Samples were re-
moved at intervals, centrifuged, washed with ice-cold M9
medium, and prepared for sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE). Radiolabeled mo-
lecular weight markers were purchased from Amersham.
RESULTS
Mapping of the fkaB gene region encoding the epitope
recognized by the anti-FHA monoclonal antibody P12H3. To
identify the region encoding the epitope recognized by
monoclonal antibody P12H3 (which was the reagent used to
detect recombinant FHA throughout this work), we cloned
subfragments of the 10-kb E6 fragment from pRMB2 (2) into
the corresponding sites of plasmid cloning vectors pEX31A
and pEX31B to obtain hybrid proteins consisting of the
NH2-terminal 98 amino acids of the MS2 replicase protein
fused in-frame to C-terminal fragments of FHA. Hybrid
plasmids were subsequently transformed into E. coli
537(pCI857TS) and, after induction at 42°C, whole-cell ex-
tracts were subjected to Western blot analysis with both
INFECT. IMMUN.
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rabbit polyclonal anti-FHA antibody and monoclonal anti-
body P12H3. The epitope recognized by the P12H3 hybrid-
oma was found to be present on the 1.0-kb BamHI-BglII
fragment of the .fhaB open reading frame (ORF) (results not
shown).
Construction of FHA expression plasmids. To construct
expression systems for producing nonfused FHA, we sub-
cloned the E6 DNA fragment into pUC18NotI (11) in both
orientations with respect to the lac promoter present in the
vector to produce hybrids pCG3 and pCG2 (Fig. 1A). The
hybrid plasmids were transformed into E. coli CAG629,
EC538, and 876; very weak expression ofFHA was detected
only with pCG3 in host strain CAG629, and only then after
induction with 1 mM IPTG (Fig. 1C, lane 5).
Expression vector pJLA503 (37) was used to construct a
system for the direct expression of FHA. This plasmid
contains thermoregulated tandem PR and PL promoters and
the highly efficient E. coli atpE translation initiation region
(TIR). The original vector multiple cloning site was modified
to construct pJLACG1 (Fig. 2A and B). This new expression
vector contained sites for cloning of the fhaB gene and
in-frame stop codons. The start codon of the fhaB ORF for
our manipulations was selected on the basis of the informa-
tion published by Domenighini et al. (6).
Hybrid plasmids pCG14 and pCG18 (Fig. 1A) were ob-
tained by subcloning the 5.9-kb SphI-BglII and 8.4-kb SphI-
SphI fragments in-frame with the ATG start codon present in
the NdeI site and the translational stop codons provided by
the linker NdeI-SalI (TAA-TAA). Four extra amino acids
are encoded between the NdeI and SphI sites of the vector
and the FHA sequence. In hybrid plasmid pCG27, these four
superfluous amino acids were removed by the addition of the
NdeI-SphI linker (Fig. 2D) to pCG14 upstream of the SphI-
BglII fragment; this linker encodes the first 15 amino acids of
FHA and was designed to optimize mRNA structure, as
predicted by the Zucker-Stiegler program (50), 50 nucleo-
tides upstream and downstream of position +1 (first nucle-
otide of the start codon), and to reduce RNA secondary
structure stability between the NH2-terminal coding region
and the atpE TIR (Fig. 2C and D). Amino acid sequence
fidelity was maintained by the mutagenesis strategy, and E.
coli major amino acid codons were preferentially used.
Hybrid plasmid pCG26 was constructed by subcloning the
3.7-kb Bglll-EcoRI fragment into pCG27. Hybrid pCG32
was obtained by digestion of pCG27 with SphI and EcoRI,
removal of the 5.9-kb SphI-EcoRI fragment, and introduc-
tion of the SphI-EcoRI linker (Fig. 2E). This recombinant
plasmid (pJLACG1 plus NdeI-SphI linker plus SphI-EcoRI
linker) was digested with SphI, and the 8.4-kb SphI-SphI
fragment was introduced.
To determine whether COOH terminus stability affects
FHA expression and to attempt to obtain the secretion of
FHA, we constructed two further clones in which the
C-terminal 23-kDa export signal of the hemolysin A gene
(hlyA) was inserted in-frame as an EcoRI-HpaI insert down-
stream of the FHA determinant of pCG26 and pCG27 to
form pCG28 and pCG29, respectively.
A third expression system used was based on plasmid
pT7-7, which contains the T7 RNA polymerase promoter
410 and the translational start site for the T7 10 protein.
Hybrids pCG30 and pCG31 were obtained by subcloning of
the NdeI fragments of pCG29 and pCG28 (the NdeI sites are
present in linker NdeI-SphI and in the sequence of the hlyA
23-kDa export signal) into the vector cut with NdeI in such
an orientation that the ATG site present in the NdeI recog-
nition sequence became the start codon. In both cases, the
Shine-Dalgarno sequence and ATG start codon were located
in regions of strong secondary structure interactions (stabil-
ity, -7.0 kcal [ca. -29 kJ]/mol) (data not shown).
Direct expression of FHA in E. coli and S. typhimurium
aroA. Hybrid plasmids pCG14, pCG18, pCG32, pCG27,
pCG26, pCG29, and pCG28 were transformed into E. coli
CAG629, EC538, and 876 and into S. typhimurium SL5283.
Plasmids isolated from the latter strain were used to trans-
form S. typhimurium SL3261 aroA, although it was not
possible to obtain transformants containing pCG28. After
induction at 42°C, total cellular extracts were subjected to
SDS-PAGE and then to Western blotting to test for the
presence of recombinant FHA (Fig. 1B and C). Expression
of FHA was found only in hybrid strains carrying plasmids
(pCG18, pCG32, pCG26, and pCG28) containing the larger
inserts. We observed important differences in expression
relating to the host strain used; these ranged from weak
expression in CAG629 to strong expression in 876 and
EC538. These data emphasize the importance of host strain
selection for the expression of FHA.
Variations in the expression efficiency were also observed
with different combinations of hybrid plasmids and host
strains: in CAG629, maximal expression was obtained with
pCG18, and less was obtained with pCG3, pCG32, and
pCG26 (Fig. 1C, lanes 5 to 8); in EC538 and 876, maximal
expression was obtained with pCG26 and pCG32, and less
was obtained pCG18 (Fig. 1C, lanes 10 to 12 and 13 to 15).
Recombinant S. typhimurium strains showed patterns of
FHA expression similar to those of EC538 and 876, with
pCG18 giving only weak signals and pCG32 and pCG26
giving much stronger signals (Fig. 1C, lanes 16 to 18).
The presence of the NdeI-SphI linker not only restored the
NH2 terminus of FHA but also generally increased its level
of expression, as can be seen when FHA yields in bacteria
containing pCG18 and pCG32 are compared (Fig. 1C, com-
pare lanes 10 and 11, lanes 13 and 14, and lanes 16 and 17).
The importance of modifications in the area of the TIR that
improve thermodynamic conditions for translation initiation
was clearly demonstrated by the results; in pCG18, in which
the theoretical value for RNA stability was high (-13.2 kcal
[ca. -55.2 kJ]/mol), although both the Shine-Dalgarno se-
quence and start codon were free of interactions (data not
shown), low expression levels were obtained, whereas in
pCG32, in which the theoretical value for RNA stability was
low (-1.5 kcal [ca. -6.3 kJ]/mol), high expression levels
were detected. Alternatively, recombinant protein stability
may be improved by the addition of NH2- and COOH-
terminal sequences.
FHA was not detected in the supernatant fluids of cultures
of induced E. coli cells containing pCG28 and pLG575
(which constitutively express the hlyB gene product, neces-
sary for the secretion of fusion proteins containing the hlyA
C-terminal 23-kDa export signal), nor was the hlyA fragment
detected in Western blots (data not shown). Therefore, FHA
was not secreted by this construct.
Hybrid plasmids pCG30 and pCG31 (pT7-7 expression
system) were introduced by transformation into E. coli
K38X(pGP1-2), BL21 DE3 (a B strain deficient in lon prote-
ase and ompT outer membrane protease), and BL21
DE3(pLysS) (a strain expressing low levels of T7 lysozyme
that inhibit the basal amount of T7 polymerase, which can
result in the expression of potentially toxic products in
uninduced cells) (41). Induction at 42°C for the first strain
and with 1 mM IPTG for the other strains produced no
detectable FHA expression (Fig. 1A). The lack of expression
may have resulted from strong RNA secondary structure
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DIRECT EXPRESSION OF B. PERTUSSIS FHA 3791
interactions in the TIR (-7.0 kcal/mol) involving both the
Shine-Dalgarno sequence and the start codon and possibly
inhibiting translation initiation.
Immunoelectron microscopy demonstrated that in E. coli
CAG629, 876, and EC538 containing pCG3, pCG18, pCG26,
pCG28, and pCG32, recombinant FHA was accumulated in
the cytoplasm as a diffuse pattern and inclusion bodies were
not observed. In contrast to the results with E. coli hybrids,
recombinant FHA was deposited in inclusion bodies in S.
typhimurium SL3261(pCG26) (results not shown).
Investigation of expressing and nonexpressing clones. To
investigate the reasons for the differential expression of
FHA in different constructs based on the pJLACG1 expres-
sion system, particularly factors such as transcription rates,
mRNA degradation, and protein stability, we transformed
hybrid plasmids pCG14, pCG18, pCG32, pCG27, pCG26,
pCG29, and pCG28 into E. coli SK5003, which is deficient in
polynucleotide phosphorylase and thermolabile for RNase
II, the two most important enzymes involved in 3'-to-5'
degradation of mRNA. After simultaneous induction and
inactivation of RNase II by shifting of bacterial cultures to
42°C for either 30 min or 1 h, the expression of FHA was
observed only from plasmids that had previously given
positive results with other host strains (e.g., Fig. 1C, lanes
19 and 20). This result suggests that the instability of mRNA
due to 3'-to-5' exonucleases is not the cause of the poor
expression of FHA in some clones.
To determine whether major differences in transcription
initiation from the lambda PR and PL promoters could
explain the differences in FHA expression, we assayed total
RNA from CAG629 containing clones pCG27 (negative
expression) and pCG26 (positive expression) by primer
extension with the FHAa probe. In both clones, transcrip-
tion was directed efficiently by the PL promoter (Fig. 3). The
start of transcription was 173 nucleotides upstream of start
codon ATG, in accordance with the PL start site (37). There
was no evidence of another start site further upstream and
corresponding to the position of the lambda PR promoter
present in the vector, consistent with the finding that less
than 5% of transcripts originated from the PR promotor in
pJLA503 (17a). Thus, poor transcription initiation is not the
cause of poor expression of FHA encoded by pCG27.
To determine whether the mRNA was degraded from the
3' end and whether transcription extended beyond the area
complementary to the FHAa probe, we bound total RNA
from CAG629 containing hybrid plasmids pCG27 and pCG29
(negative expression) and pCG26 and pCG28 (positive
expression) to nylon membranes and hybridized it with
probes complementary to different areas of the fAaB ORF(FHAa, FHAb, FHAc, FHAd, FHAe, FHAf, FHAg, and
FHAh; see Materials and Methods). Hybridization was also
carried out with probes complementary to the vector DNA
sequence upstream from the start of transcription (jlaSOJ,
negative control) and to the hemolysin 23-kDa COOH-
terminal signal (Hlyl). No hybridization signals were de-
tected with the jlaS01, Hlyl, or FHAh probes with RNA
from any of the four strains tested. In contrast, good
hybridization signals were obtained with probes FHAa,
FHAb, FHAc, FHAd, FHAe, FHAf, and FHAg with RNA
from all strains (expressing and nonexpressing clones) (Fig.
3C). This result indicates that the major portion of the FHA
gene is transcribed and that the resulting mRNA is reason-
ably stable in all clones.
To analyze possible differences in efficiencies of transla-
tion and stability of the translation product, we performed
pulse-chase experiments with E. coli EC538 containing
pCG27 and pCG26. After induction, a 5-min pulse with
35S-methionine, and chases varying from 5 to 60 min with
cold methionine, the major 200- to 220-kDa band was clearly
seen in EC538(pCG26) and persisted without change for at
least 1 h (Fig. 3D, lanes 1 to 4). In corresponding experi-
ments, this band was not detected in cells containing the
vector without the insert (data not shown). Analysis of other
FHA bands was not possible because of the presence of
background proteins encoded by other mRNA species and
the appearance and disappearance of other proteins because
of the effects of heat shock. The 200- to 220-kDa band was
also produced by EC538(pCG27) but was very weak (Fig.
3D, lanes 5 to 8), suggesting differences between pCG26 and
pCG27 in mRNA translation efficiencies.
DISCUSSION
FHA is an important adhesin involved in the early inter-
actions between B. pertussis and host cells (44, 45). It is a
major candidate antigen for incorporation into a new gener-
ation of safer vaccines against whooping cough. Until now,
however, its production from B. pertussis has been proble-
matic with regard to slow growth rates, low yields, and
contamination with pertussis determinants involved in ad-
verse reactions. The goal of the present effort has been to
determine conditions that allow high-level expression of
nonfused FHA in E. coli.
The estimated coding region for the 200- to 220-kDa FHA
protein secreted from B. pertussis is 6.2 kb, approximately
the size of the SphI-BglII fragment. However, the FHA ORF
extends over 11 kb. In experiments with E. coli and S.
typhimurium containing pJLACG1-derived hybrid plasmids,
only those inserts extending beyond the coding region for the
secreted 200- to 220-kDa protein yielded good expression of
FIG. 1. Expression of nonfused FHA in E. coli and S. typhimurium aroA. (A) Diagrammatic representation of plasmids constructed to
investigate FHA expression. The presence or absence of the NdeI-SphI linker (see Fig. 2D) is indicated by short solid boxes. Hatched bars
correspond to thefhaB gene sequences present in different hybrids. The EcoRI-HpaI fragment encoding the 23-kDa C terminus of the E. coli
hemolysin (Hly) is represented by long solid boxes. The level of FHA expression, as determined by Western blot analysis with monoclonal
antibody P12H3, ranged from no expression (-) to strong expression (+++). The EcoRI-NdeI DNA fragment encoding part of the hlyA
23-kDa C terminus is shown as partly solid, partly open boxes. Open boxes correspond to the fhaB gene sequences not present in different
hybrids. Arrows indicate the gene orientation with respect to the lac promoter present in vector pUC18NotI. NT, not tested. The main
restriction sites for genetic manipulations are shown. DNA fragments are not drawn to scale. (B) SDS-PAGE with Coomassie blue staining
of total cellular extracts. (C) Western blot analysis with monoclonal antibody P12H3 of total cellular extracts. Lanes: 1, molecular weight
standards (in thousands); 2, purified FHA from B. pertussis Tohama; 3, B. pertussis Tohama; 4 to 8, E. coli CAG629 containing pUC18NotI
(4), pCG3 (5), pCG18 (6), pCG32 (7), and pCG26 (8); 9 to 12, E. coli EC538 containing pJLACG1 (9), pCG18 (10), pCG32 (11), and pCG26
(12); 13 to 15, E. coli 876 containing pCG18 (13), pCG32 (14), and pCG26 (15); 16 to 18, S. typhimurium SL3261 aroA containing pCG18 (16),
pCG32 (17), and pCG26 (18); 19 and 20, E. coli SK5003 containing pCG26 (19) and pCG27 (20). The main Coomassie blue-stained FHA bands
are indicated by an arrow. In all cases, inductions were performed at 42°C for 1 h.
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FIG. 2. Construction of plasmids for the direct expression of FHA. (A) Expression plasmid pJLACG1, which contains the lambda PR and
PL promoters in tandem (solid arrows), the atpE TIR (AtpE; solid box), the fd transcriptional terminator, the P-lactamase gene (bla), the
thermosensitive repressor (cIts857), and the NdeI-SaIl multiple cloning site (MCS; open box). (B) SphI-SalI linker used to modify the MCS
of pJLA503 to construct pJLACG1 and allow the subcloning of different DNA fragments encoding FHA into the expression vector. (C and
D) Original (C) and modified (D) coding regions of the NdeI-SphI linker. The nucleotide sequence of the N-terminal region of FHA is given
in one-letter codes. The NdeI (CATATG) and SphI (GCATGC) restriction sites are indicated. Base pair changes corresponding to differences
between the original nucleotide sequence and the synthetic oligonucleotide linker NdeI-SphI are indicated by small arrows; large arrows
delineate part of the atpE translation initiation region present in expression plasmid pJLACG1. The RNA stability +50 bases from the ATG
start codon was calculated by the method of Zucker and Stiegler (50); 1 cal = 4.184 J. (E) Sphl-EcoRL linker used to obtain pCG32. Boxes
indicate the oligonucleotide linkers.
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FIG. 3. (A) Reverse transcriptase mapping of the transcriptional start site of the recombinant FHA gene carried by pCG27 and pCG26.
Lanes G, A, T, and C contain DNA sequence reactions of pCG27 with the FHAa primer. Primer extension with RNA preparations isolated
from CAG629 containing pCG27 (lane 1) and pCG26 (lane 2) following induction at 42'C for 30 min was carried out with the FHAa primer.
The transcriptional start site at base A -173 and the position of the first base in the RNA message and the adenosine (base +1) of the ATG
start codon are indicated by arrows. (B) Sequence of the upstream region of the recombinant FHA gene. The transcriptional start site relative
to the ATG start codon is indicated by an arrow. The ATG start codon and concensus Shine-Dalgarno region (SD) are underlined. (C)
Diagrammatic representation of the results of total RNA dot blot hybridizations of CAG629 containing pCG27, pCG29, pCG26, and pCG28.
The probes were jlaSOI (1), FHAa (2), FHAb (3), FHAc (4), FHAd (5), FHAe (6), FHAf(7), FHAg (8), FHAh (9), and Hlyl (10). The probes
are shown in approximate correspondence to their positions in the DNA sequence. The fhaB gene sequence is indicated as a hatched box.
NP, fragment not present in the hybrid. + and - indicate the presence or absence of hybridization. (D) Pulse-chase experiments with E. coli
EC538 containing pCG26 (lanes 1 to 4) and pCG27 (lanes 5 to 8), corresponding to time zero (uninduced) (lanes 1 and 5) and 10 min (lanes
2 and 6), 20 min (lanes 3 and 7), and 30 min (lanes 4 and 8) after induction. The arrow indicates the main protein product.
FHA. Several experiments were carried out to study the lack
of expression of FHA from constructs not containing the
COOH-terminal portion of the FHA ORF. The results ob-
tained indicated that mRNA synthesis and stability were not
the cause of the difference and that perhaps mRNA transla-
tion was lower in constructs with low expression. Interest-
ingly, probes FHAh and Hlyl, specific for the nonexpressed
C-terminal portion of the FHA ORF and for the coding
region of the C terminus of hemolysin in FHA-hemolysin
fusions, respectively, failed to hybridize either to expressing
or to nonexpressing clones (Fig. 3C). This result reflected
the failure to detect HlyA protein with a specific polyclonal
antiserum against the COOH terminus of hemolysin (data
not shown) and suggested that in E. coli the region down-
stream of the FHAg probe either was not transcribed or was
highly unstable. The requirement of this region for FHA
expression in E. coli is therefore surprising. The DNA
fragment present in expressing clones between the FHAg
and FHAh probes may encode a peptide sequence which is
involved in the stability of the major FHA band. In cellular
extracts of B. pertussis, proteins that reacted with antibodies
raised against fusion proteins with the COOH-terminal part
of the FHA ORF were detected (6). Extracts of B. bronchi-
septica and B. parapertussis did not react with such anti-
bodies. These results highlight the need for further investi-
gations to elucidate the function of the COOH-terminal part
of FHA in both E. coli and Bordetella spp. It would in any
case seem that a number of factors, including mRNA insta-
bility, the levels of proteases produced in different E. coli
strains, the preferential degradation of recombinant FHA
due to the absence of protein signals found in expressing
clones, and the inherent instability of the FHA protein, may
strongly influence levels of expression of recombinant FHA.
The expression of hybrid plasmids in strains EC538 and
876 yielded higher levels of FHA than those observed in
wild-type B. pertussis Tohama. The protein was highly
degraded in both strain Tohama and recombinant clones.
However, this degradation may not be critical for FHA
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incorporated into vaccines. The high-level production of a
recombinant protein as an intracytoplasmic protein that was
not apparently precipitated as inclusion bodies in E. coli
strains when clones based on the pJLACG1 vector were
used should facilitate recombinant FHA purification by
avoiding harsh solubilization procedures and the need to
separate FHA from membranes, thereby also reducing the
problem of removal of lipopolysaccharide contamination
during FHA purification.
To our knowledge, this is the first report of the high-level
expression of nonfused FHA in E. coli. However, several
fusion proteins containing part of the FHA ORF were
obtained by other authors (1, 4). Recently, Molina and
Parker (18) and Parker et al. (19) detected FHA-specific
immunoglobulin G in serum following immunization of mice
with attenuated Salmonella sp. strains expressing truncated
FHA.
The hyperexpression of recombinant FHA in E. coli,
resulting in its biological separation from other pertussis
virulence determinants, provides a solution to the problem
of contamination of FHA preparations with other Bordetella
virulence products and should advance the development of a
recombinant subunit vaccine against whooping cough. The
expression of FHA in E. coli also resolves the difficulties
associated with fermenting large quantities of a fastidious,
slow-growing human pathogen. The large-scale production
of purified FHA may lead to the development of kits for
serological studies without the need to culture B. pertussis.
The expression of FHA in S. typhimurium aroA mutants
offers the possibility for the construction of live vaccine
carrier strains of Salmonella spp. expressing pertussis anti-
gens and may provide the opportunity to develop oral
whooping cough vaccines that stimulate both mucosal and
systemic immunity (12, 13). These results would appear to
open new perspectives for the development of both subunit
and live vaccines against whooping cough.
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